Medtronic plc (MDT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Medtronic plc (MDT) Healthcare & Pipeline Overview

Medtronic plc, a global medical device giant, pioneers innovative therapies across cardiovascular, medical-surgical, neuroscience, and diabetes sectors. With a diverse portfolio and extensive global reach, Medtronic addresses critical healthcare needs, maintaining a strong market presence through continuous innovation and strategic acquisitions, while facing increasing regulatory scrutiny and competition.

What Is the Investment Thesis for MDT?

Medtronic presents a compelling, albeit moderate, investment thesis centered on its established market leadership and consistent dividend payouts (3.73% yield). The company's diverse portfolio across multiple healthcare segments provides resilience against sector-specific downturns. Growth catalysts include the ongoing adoption of robotic-assisted surgery and continuous glucose monitoring systems. However, potential risks include increasing competition from emerging medical device companies and regulatory hurdles for new product approvals. Investors should monitor Medtronic's ability to maintain its profit margin (13.0%) amid pricing pressures and its success in integrating acquired technologies to drive future growth.

Based on FMP financials and quantitative analysis

MDT Key Highlights

Market Cap of $119B reflects Medtronic's significant presence and stability in the medical device industry.

• P/E Ratio of 21.1 indicates a moderate valuation compared to its earnings, suggesting reasonable investor expectations.
• Gross Margin of 61.9% demonstrates strong pricing power and efficient cost management in its manufacturing processes.
• Dividend Yield of 3.73% provides a steady income stream for investors, highlighting Medtronic's commitment to returning value.
• Beta of 0.76 suggests lower volatility compared to the overall market, making it a relatively stable investment option.

Who Are MDT's Competitors?

MDT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MDT's Key Strengths?

Diversified product portfolio across multiple healthcare segments

• Strong brand recognition and global presence
• Extensive research and development capabilities
• Established relationships with healthcare providers

What Are MDT's Weaknesses?

Exposure to regulatory risks and product recalls

• Dependence on innovation for growth
• Pricing pressures from healthcare cost containment
• Integration challenges with acquired companies

What Could Drive MDT Stock Higher?

Regulatory approvals for new products in key markets.

• Expansion of robotic-assisted surgery platform into new surgical specialties.
• Increasing adoption of continuous glucose monitoring systems.
• Results from clinical trials for novel therapies.

What Are the Key Risks for MDT?

Product recalls or safety concerns.

• Intense competition from other medical device companies.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturns affecting healthcare spending.
• Cybersecurity threats to medical devices and patient data.

What Are the Growth Opportunities for MDT?

• Expansion of Robotic-Assisted Surgery: Medtronic's Hugo robotic-assisted surgery system represents a significant growth opportunity. The global surgical robotics market is projected to reach $14.7 billion by 2028, growing at a CAGR of 12.8%. By expanding the capabilities of the Hugo system and securing regulatory approvals in key markets, Medtronic can capture a larger share of this rapidly growing market, offering surgeons enhanced precision and minimally invasive options.
• Growth in Continuous Glucose Monitoring (CGM): The market for continuous glucose monitoring systems is expanding rapidly, driven by the increasing prevalence of diabetes. Medtronic's CGM systems offer patients real-time glucose data, enabling better diabetes management. The global CGM market is expected to reach $10.4 billion by 2027. By innovating its CGM technology and expanding its reach to more patients, Medtronic can capitalize on this growing market.
• Emerging Markets Expansion: Growth in emerging markets, particularly in Asia-Pacific and Latin America, presents a significant opportunity for Medtronic. These regions are experiencing increasing healthcare spending and a growing demand for advanced medical technologies. By tailoring its products and services to meet the specific needs of these markets and establishing strategic partnerships with local healthcare providers, Medtronic can drive revenue growth and expand its global footprint.
• Strategic Acquisitions and Partnerships: Medtronic has a history of driving growth through strategic acquisitions and partnerships. By acquiring companies with complementary technologies and capabilities, Medtronic can expand its product portfolio and enter new market segments. For example, acquiring a company specializing in artificial intelligence for medical imaging could enhance Medtronic's diagnostic capabilities and improve patient outcomes. These strategic moves can accelerate innovation and drive long-term growth.
• Advancements in Cardiovascular Devices: The cardiovascular device market continues to evolve with advancements in minimally invasive procedures and remote monitoring technologies. Medtronic is well-positioned to capitalize on these trends with its portfolio of pacemakers, defibrillators, and related products. By developing next-generation cardiovascular devices that offer improved performance and patient outcomes, Medtronic can maintain its leadership position in this critical market segment. The global cardiovascular device market is projected to reach $60 billion by 2028.

What Are MDT's Competitive Advantages?

• Extensive product portfolio across multiple medical specialties.
• Strong brand reputation and established relationships with healthcare providers.
• Significant investment in research and development, leading to innovative products.
• Global presence and distribution network.
• High switching costs for customers due to the critical nature of medical devices.

What Does MDT Do?

Founded in 1949 in a Minneapolis garage by Earl Bakken and Palmer Hermundslie, Medtronic initially focused on repairing medical equipment. The company's early breakthrough came with the development of a wearable, battery-powered pacemaker, revolutionizing cardiac care. Over the decades, Medtronic expanded its portfolio through strategic acquisitions and internal innovation, growing into a global leader in medical technology. Today, Medtronic develops, manufactures, and sells a wide range of device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates through four main segments: Cardiovascular Portfolio, which includes pacemakers, defibrillators, and related products; Medical Surgical Portfolio, offering surgical staplers, vessel sealers, and robotic-assisted surgery products; Neuroscience Portfolio, providing products for spinal surgery, neurosurgery, and pain management; and the Diabetes Operating Unit, which focuses on insulin pumps and continuous glucose monitoring systems. Medtronic's products are used in a variety of medical procedures, from cardiac rhythm management to spinal surgery and diabetes management. With a presence in over 150 countries, Medtronic serves a global customer base, addressing diverse healthcare needs with its innovative technologies. The company's headquarters are in Dublin, Ireland, reflecting its international scope and strategic focus on global markets.

What Products and Services Does MDT Offer?

• Develops and manufactures implantable cardiac pacemakers and defibrillators.
• Offers surgical stapling devices and vessel sealing instruments.
• Provides products for spinal surgery, neurosurgery, and pain management.
• Manufactures insulin pumps and continuous glucose monitoring systems.
• Offers products for treating vasculature in and around the brain.
• Provides remote monitoring and patient-centered software solutions.
• Develops robotic-assisted surgery products.

How Does MDT Make Money?

• Develops and manufactures medical devices and therapies.
• Sells products directly to healthcare systems, physicians, and patients.
• Generates revenue through product sales and related services.
• Invests in research and development to innovate new products and improve existing ones.

What Industry Does MDT Operate In?

Medtronic operates within the dynamic medical device industry, characterized by continuous innovation and evolving regulatory landscapes. The industry is driven by an aging global population, increasing prevalence of chronic diseases, and technological advancements in medical treatments. Competition is intense, with major players like Bristol-Myers Squibb Company (BMY) and Sanofi (SNY) vying for market share. Medtronic's diversified portfolio and global reach position it favorably to capitalize on industry growth, estimated at 5-7% annually, while navigating regulatory challenges and pricing pressures.

Who Are MDT's Key Customers?

• Healthcare systems and hospitals
• Physicians and surgeons
• Clinicians and medical professionals
• Patients requiring medical device therapies

Medtronic plc (MDT) Valuation Context

Valued at $119B, MDT is classified as a large-cap stock. Relative to its peer group, MDT's quantitative score of 77/100 is roughly in line with the peer average of 75/100.

MDT Revenue & Earnings Trend

In Q2 2026, MDT generated $9.81B in top-line revenue, marking a sequential increase of 8.7%. The company recorded net income of $1.24B, with diluted EPS of $0.96. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, MDT averaged $0.93 in diluted EPS.

Company Profile

Medtronic plc operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Galway, IE. The company is led by CEO Geoffrey Straub Martha. MDT has traded publicly since 1973.

Return on equity for Medtronic plc stands at 9.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.2%, showing how much profit it generates from its asset base. MDT trades at a trailing price-to-earnings ratio of 21.15, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.3%, the inverse of the P/E and a quick read on earnings relative to price.

Medtronic plc's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.94 places it in the grey zone, a middle ground that warrants monitoring.

Medtronic plc has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.1% above estimates on average.

Wall Street analysts project Medtronic plc revenue of about $36.15B for fiscal 2026, with EPS near $5.52. The estimate reflects 11 contributing analysts.

MDT Financials

MDT earnings history & estimates →

MDT Latest News

MDT Analyst Consensus

MDT MoonshotScore

Medtronic plc Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources